# A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

> **NCT01054456** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 36 (actual)

## Conditions studied

- Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

## Interventions

- **DRUG:** palonesetron

## Key facts

- **NCT ID:** NCT01054456
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-27
- **Primary completion:** 2010-12-08
- **Final completion:** 2010-12-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01054456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01054456, "A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01054456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*